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Department of Medicine I, University Medical Centre Hamburg-Eppendorf, Hamburg, GermanySee Article, pages 53–60Infections with the hepatitis B virus (HBV) or hepatitis C virus
(HCV) are the major causes of liver cirrhosis and liver cancer
worldwide [1]. Both viruses induce an acute necroinﬂammatory
liver disease that may result in clearance of the virus in some
patients, while evolving into a chronically persisting viral infec-
tion in other patients [1]. Whether the virus can be cleared or
persists seems to depend largely on the vigour and speciﬁcity
of the T cell response to the virus [1]. Therefore, the major focus
of research has been on the reasons for the functional deteriora-
tion of the anti-viral T cell response and, indeed, considerable
progress is being made in identifying potential targets for restor-
ing T cell function [1,2]. The role of B cells in HBV and HCV infec-
tion, however, is much less in the focus of attention, and only few
studies have addressed this subject. In a paper within this issue,
Oliviero et al. take a fresh look at the role of B cells in chronic HBV
and HCV infection by assessing B cell phenotype and function [3].
Although it is widely accepted that the anti-viral T cell
response determines whether HBV or HCV infection can be
resolved or may persist, there are several reasons to also investi-
gate the B cell response to HBV and HCV infection. (1) The
anti-viral B cell response is clinically relevant. Notably in HCV
infection, polyclonal B cell activation can cause cryoglobulinemia
and induce vasculitis, arthritis, or glomerulonephritis [4]. More-
over, such chronic B cell activation can evolve into malignancies,
such as non-Hodgkin’s lymphoma [5]. (2) B cells can capture and
present speciﬁc antigens very efﬁciently and, therefore, virus-
speciﬁc B cells are important activators for anti-viral T cells.
Indeed, it has been shown that the generation of virus-speciﬁc
memory CD4 T cells required the presentation of viral antigens
by B cells [6]. This antigen presenting capability of B cells may
be of particular relevance for HCV infection, which is frequently
marked by the formation of ectopic lymphoid tissue in the portal
tract of the liver. These ectopic lymph follicles within the liver
allow for an efﬁcient mutual stimulation of T cells and B cells.
(3) In animal models, antigen-presentation by B cells has been
found to induce immune tolerance rather than inﬂammatory
responses that would favour viral elimination [7]. Indeed, it hasJournal of Hepatology 20
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death-1.been shown that the interaction of T cells with B cells seems to
up-regulate the negative co-stimulatory molecule PD-1 [7],
which is also a marker for T cell exhaustion and known to pro-
mote viral persistence [8]. Moreover, B cells, at least in mice,
are major sources of the anti-inﬂammatory cytokine interleu-
kin-10 [9] that has also been shown to promote viral persistence
in vivo [10]. Thus, B cells seem to feature at least two non-
redundant mechanisms that inhibit viral elimination in vivo
[9,10]. (4) By secreting neutralizing antibodies, B cells can limit
viral infection and contribute signiﬁcantly to viral elimination
[11]. Indeed, the presence of neutralizing antibodies during the
acute phase of HCV infection was associated with viral clearance
[12]. However, neutralizing antibodies to HBV or HCV are fre-
quently lacking in the acute phase of infection and often develop
only in the chronic phase [1,13]. This retarded development of
neutralizing antibodies is probably caused by a strong anti-viral
CD4 T cell response, which favours polyclonal B cell activation
rather than focusing on neutralizing antibodies [11,14,15].
Indeed, experimental reduction in CD4 T cell help in vivo facili-
tated the development of a potent neutralizing antibody response
[14]. Recent ﬁndings demonstrated an important role in viral
clearance not only for neutralizing antibodies, but also for non-
neutralizing antibodies and early IgM antibodies [16] (Fig. 1).
Thus, B cells can inﬂuence the course of viral infections in
several ways and it appears that the role of B cells in HBV or
HCV infections may have been underestimated. In order to
approach the elusive role of B cells in HBV and HCV infection,
the paper by Oliviero et al. addressed the extent of B cell activation
and differentiation in HBV and HCV patients with chronically per-
sisting infections [3]. The authors found a high frequency of acti-
vated B cells, both in patientswith chronic HBV and HCV infection,
and both in the naive and the memory B cell pool. The B cells did
not exhibit increased markers of exhaustion. Notably the memory
B cells in chronic HBV and HCV infection showed a high expres-
sion of CXCR3, which is required for migration to sites of inﬂam-
mation. Upon stimulation by toll-like receptor engagement or
combined CD40L and interleukin-10 stimulation, the memory B
cells both from HBV and HCV carriers exhibited a relatively low
rate of differentiation into plasma cells; the proliferative response
of stimulated naive and memory B cells from virus carriers was
lower than that of healthy donors. These ﬁndings seem to indicate
that polyclonal B cell activation, at least to a certain degree, is a
feature of chronic HCV infection, as well as of chronic HBV
infection. Nevertheless, the rate of memory B cell proliferation11 vol. 55 j 5–7
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Fig. 1. Mutual interactions between B cells and CD4 T cells in viral hepatitis. (A) Efﬁcient uptake and presentation of virus by virus-speciﬁc B cells induces expansion of
memory T cells and tolerogenic CD4 T cell stimulation through interleukin-10 and PD-1 up-regulation. (B) Vigorous anti-viral CD4 T cell response induces polyclonal B cell
activation; moderate anti-viral T cell response favours neutralizing antibody formation.
Editorialand differentiation to plasma cells was low, which may explain
why none of the patients exhibited cryoglobulinemia.
It now remains to be seen to which extent the observed B
cell phenotype in chronic HBV or HCV carriers is of relevance
for shaping the anti-viral T cell response. While it is clear that
antigen-presenting B cells are capable of modulating T cell
responses, it is not clear whether the B cells from chronic
HBV or HCV carriers make use of this capability. Therefore, it
should be studied whether B cells from chronic HBV or HCV
carriers secrete elevated amounts of interleukin-10 or induce
the up-regulation of PD-1 molecules in stimulated T cells. Is
the outcome of T cell stimulation by B cells different from that
of other antigen-presenting cells from chronic virus carriers? Do
B cells induce T cell exhaustion; and, vice versa, do exhausted T
cells induce the characteristic B cell phenotype of chronic
carriers? Could therapeutic restoration of T cell function, for
which several molecular targets have been deﬁned [2], alter
the phenotype and function of B cells in chronic viral hepatitis?
We believe that it may be worthwhile to include the B cell into
the focus of research in viral hepatitis.Conﬂict of interest
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